Background Drug resistance continues to be a major limiting factor across diverse anti-
cancer therapies. Contributing to the complexity of this challenge is cancer plasticity, in …

HER2-positive breast cancers may lose HER2 expression in recurrences and metastases. In
this work, we studied cell lines derived from two transgenic mammary tumors driven by …

It is unclear as to whether Wilms' tumor 1-associated protein (WTAP) promotes or
suppresses breast cancer. This immunohistochemistry analysis explored levels of WTAP …

Heterogeneity and drug resistance of tumor cells are the leading causes of incurability and
poor survival for patients with recurrent breast cancer. In order to accurately deliver the …

Background Biomarker discrepancy between primary and recurrent/metastatic breast cancer
is well known, however its impact on prognosis and treatment after relapse is still unclear …

Elevated levels of resistin and epidermal growth factor receptor (EGFR) facilitate the
development of breast cancer, although there are no reports of any correlation between …

It is unclear whether the methyltransferase‐like 14 (METTL14) protein promotes or
suppresses cancer growth. We examined the association between METTL14 expression …

Triple-negative breast cancer refers to breast cancer patients with negative estrogen
receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor …

Background One of the manifestations of recurrence after mastectomy is the presentation of
chest wall lesion. However, it is unclear if the size of the chest wall recurrence (CWR) is …

Immunophenotypic discordance of receptors between primary and metastatic sites
significantly impacts treatment outcomes. Current international guidelines recommend …